{"name":"Seattle Genetics","permalink":"seattle-genetics","crunchbase_url":"http://www.crunchbase.com/company/seattle-genetics","homepage_url":"http://www.seagen.com/","blog_url":"","blog_feed_url":"","twitter_username":"","category_code":"biotech","number_of_employees":null,"founded_year":null,"founded_month":null,"founded_day":null,"deadpooled_year":null,"deadpooled_month":null,"deadpooled_day":null,"deadpooled_url":null,"tag_list":"","alias_list":"","email_address":"contact@seagen.com","phone_number":"(425) 527-4000","description":"","created_at":"Wed Jan 19 02:23:47 UTC 2011","updated_at":"Thu Feb 03 06:48:11 UTC 2011","overview":"<p>Seattle Genetics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases. Its lead product, SGN-35, is in pivotal trial for patients with relapsed or refractory hodgkin lymphoma. The companyâ€™s other product candidates in various stages of clinical trials include dacetuzumab (SGN-40), a humanized anti-CD40 antibody; lintuzumab (SGN-33), a humanized anti-CD33 antibody; SGN-70, a humanized anti-CD70 antibody for the treatment of autoimmune diseases; SGN-75, which is in Phase I clinical trials for metastatic renal cell carcinoma and non-Hodgkin lymphoma; ASG-5ME, a preclinical antibody-drug conjugate product candidate for the treatment of solid tumors; and SGN-19A, a preclinical antibody-drug conjugate product candidate for the treatment of hematologic malignancies. It has collaborations with Bayer Pharmaceuticals Corporation; Celldex Therapeutics, Inc.; Daiichi Sankyo Co., Ltd.; Genentech; GlaxoSmithKline LLC; MedImmune, Inc.; Millennium; PSMA Development Company LLC; and Genmab A/S. The company also has an antibody-drug conjugates co-development agreement with Agensys, Inc. The company was founded in 1997 and is headquartered in Bothell, Washington.</p>","image":{"available_sizes":[[[150,38],"assets/images/resized/0011/7993/117993v1-max-150x150.jpg"],[[250,64],"assets/images/resized/0011/7993/117993v1-max-250x250.jpg"],[[331,85],"assets/images/resized/0011/7993/117993v1-max-450x450.jpg"]],"attribution":null},"products":[],"relationships":[{"is_past":false,"title":"President and CEO","person":{"first_name":"Clay","last_name":"B. Siegall","permalink":"clay-b-siegall","image":null}},{"is_past":false,"title":"CFO","person":{"first_name":"Todd","last_name":"E. Simpson","permalink":"todd-e-simpson","image":null}}],"competitions":[],"providerships":[],"total_money_raised":"$155M","funding_rounds":[{"round_code":"unattributed","source_url":"http://www.fiercebiotech.com/story/seattle-genetics-raises-155m-chelsea-splits-trial-northera/2011-02-02?utm_medium=rss&utm_source=rss","source_description":"Seattle Genetics raises $155M; Chelsea splits trial for Northera","raised_amount":155000000,"raised_currency_code":"USD","funded_year":2011,"funded_month":2,"funded_day":2,"investments":[]}],"investments":[],"acquisition":null,"acquisitions":[],"offices":[{"description":"","address1":"21823 - 30th Drive S.E.","address2":"","zip_code":"98021","city":"Bothell","state_code":"WA","country_code":"USA","latitude":null,"longitude":null}],"milestones":[{"description":"Seattle Genetics scores $208M Pfizer pact for ADC tech","stoned_year":2011,"stoned_month":1,"stoned_day":6,"source_url":"http://www.fiercebiotech.com/story/seattle-genetics-scores-208m-pfizer-pact-adc-tech/2011-01-06?utm_medium=rss&utm_source=rss","source_text":"","source_description":"Seattle Genetics scores $208M Pfizer pact for ADC tech","stoneable_type":"Company","stoned_value":null,"stoned_value_type":null,"stoned_acquirer":null,"stoneable":{"name":"Seattle Genetics","permalink":"seattle-genetics"}}],"ipo":{"valuation_amount":null,"valuation_currency_code":"USD","pub_year":null,"pub_month":null,"pub_day":null,"stock_symbol":"NASDAQ:GM"},"video_embeds":[],"screenshots":[],"external_links":[]}